THANZY PHARM SOLUTIONS LIMITED

Company Registration Number:
09668302 (England and Wales)

Unaudited statutory accounts for the year ended 31 July 2024

Period of accounts

Start date: 01 August 2023

End date: 31 July 2024

THANZY PHARM SOLUTIONS LIMITED

Contents of the Financial Statements

for the Period Ended 31 July 2024

Company Information - 3
Report of the Directors - 4
Balance sheet - 5
Additional notes - 7
Balance sheet notes - 10

THANZY PHARM SOLUTIONS LIMITED

Company Information

for the Period Ended 31 July 2024




Director: THANDAZANI NCUBE
Secretary: THANDAZANI NCUBE
Registered office: 3
Mokyll Croft
Taverham
Norwich
England
NR8 6UG
Company Registration Number: 09668302 (England and Wales)

THANZY PHARM SOLUTIONS LIMITED

Directors' Report Period Ended 31 July 2024

The directors present their report with the financial statements of the company for the period ended 31 July 2024

Principal Activities

The principal activity of the company throughout the period was provision of scientific and technical Services.

Directors

The directors shown below have held office during the whole of the period from 01 August 2023 to 31 July 2024
THANDAZANI NCUBE

Secretary
THANDAZANI NCUBE

This report was approved by the board of directors on 17 October 2024
And Signed On Behalf Of The Board By:

Name: THANDAZANI NCUBE
Status: Director

THANZY PHARM SOLUTIONS LIMITED

Balance sheet

As at 31 July 2024


Notes

2024
£

2023
£
Fixed assets
Tangible assets: 4 2,800 2,133
Total fixed assets: 2,800 2,133
Current assets
Debtors: 5 82 202
Cash at bank and in hand: 1,643 466
Total current assets: 1,725 668
Creditors: amounts falling due within one year: 6 ( 650 ) ( 650 )
Net current assets (liabilities): 1,075 18
Total assets less current liabilities: 3,875 2,151
Creditors: amounts falling due after more than one year: 7 ( 19,809 ) ( 16,521 )
Total net assets (liabilities): ( 15,934 ) ( 14,370 )

The notes form part of these financial statements

THANZY PHARM SOLUTIONS LIMITED

Balance sheet continued

As at 31 July 2024


Notes

2024
£

2023
£
Capital and reserves
Called up share capital: 100 100
Profit and loss account: ( 16,034 ) ( 14,470 )
Shareholders funds: ( 15,934 ) ( 14,370 )

For the year ending 31 July 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 17 October 2024
And Signed On Behalf Of The Board By:

Name: THANDAZANI NCUBE
Status: Director

The notes form part of these financial statements

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

  • 2. Employees


    2024

    2023
    Average number of employees during the period 1 1

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

  • 3. Off balance sheet disclosure

    No

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

4. Tangible assets

Plant & machinery Total
Cost £ £
At 01 August 2023 22,313 22,313
Additions 3,500 3,500
Disposals - -
Revaluations - -
Transfers - -
At 31 July 2024 25,813 25,813
Depreciation
At 01 August 2023 20,180 20,180
Charge for year 2,833 2,833
On disposals - -
Other adjustments - -
At 31 July 2024 23,013 23,013
Net book value
At 31 July 2024 2,800 2,800
At 31 July 2023 2,133 2,133

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

5. Debtors


2024
£

2023
£
Trade debtors 82 202
Total 82 202

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

6.Creditors: amounts falling due within one year note


2024
£

2023
£
Other creditors 650 650
Total 650 650

THANZY PHARM SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2024

7.Creditors: amounts falling due after more than one year


2024
£

2023
£
Other creditors 19,809 16,521
Total 19,809 16,521